Coronavirus disease 2019 (COVID-19) presents a clinical spectrum that ranges from a mild condition to critical illness. Patients with critical illness present respiratory failure, septic shock and/or multi-organ failure induced by the so called “cytokine storm”. Inflammatory cytokines affect iron metabolism, mainly inducing the synthesis of hepcidin, a hormone peptide not routinely measured. High levels of hepcidin have been associated with the severity of COVID-19. The aim of this study was to analyze, retrospectively, the levels of hepcidin in a group of COVID-19 patients admitted to the intensive care unit (ICU) of the Policlinico Tor Vergata of Rome, Italy. Thirty-eight patients from November 2020 to May 2021 were enrolled in the study. Based on the clinical outcome, the patients were assigned to two groups: survivors and non-survivors. Moreover, a series of routine laboratory parameters were monitored during the stay of the patients in the ICU and their levels correlated to the outcome. Statistical differences in the level of hepcidin, D-dimer, IL-6, LDH, NLR, neutrophils level, CRP, TNF-α and transferrin were observed between the groups. In particular, hepcidin values showed significantly different median concentrations (88 ng/mL vs. 146 ng/mL) between survivors and non-survivors. In addition, ROC curves analysis revealed sensitivity and specificity values of 74% and 76%, respectively, at a cut-off of 127 (ng/mL), indicating hepcidin as a good biomarker in predicting the severity and mortality of COVID-19 in ICU patients.

Evaluation of hepcidin level in covid-19 patients admitted to the intensive care unit / Ciotti, Marco; Nuccetelli, Marzia; Pieri, Massimo; Maria Petrangeli, Carlo; Giovannelli, Alfredo; Cosio, Terenzio; Rosa, Luigi; Valenti, Piera; Leonardis, Francesca; Maria Legramante, Jacopo; Bernardini, Sergio; Campione, Elena; Minieri, Marilena. - In: DIAGNOSTICS. - ISSN 2075-4418. - 12:11(2022), pp. 1-9. [10.3390/diagnostics12112665]

Evaluation of hepcidin level in covid-19 patients admitted to the intensive care unit

Luigi Rosa;Piera Valenti;
2022

Abstract

Coronavirus disease 2019 (COVID-19) presents a clinical spectrum that ranges from a mild condition to critical illness. Patients with critical illness present respiratory failure, septic shock and/or multi-organ failure induced by the so called “cytokine storm”. Inflammatory cytokines affect iron metabolism, mainly inducing the synthesis of hepcidin, a hormone peptide not routinely measured. High levels of hepcidin have been associated with the severity of COVID-19. The aim of this study was to analyze, retrospectively, the levels of hepcidin in a group of COVID-19 patients admitted to the intensive care unit (ICU) of the Policlinico Tor Vergata of Rome, Italy. Thirty-eight patients from November 2020 to May 2021 were enrolled in the study. Based on the clinical outcome, the patients were assigned to two groups: survivors and non-survivors. Moreover, a series of routine laboratory parameters were monitored during the stay of the patients in the ICU and their levels correlated to the outcome. Statistical differences in the level of hepcidin, D-dimer, IL-6, LDH, NLR, neutrophils level, CRP, TNF-α and transferrin were observed between the groups. In particular, hepcidin values showed significantly different median concentrations (88 ng/mL vs. 146 ng/mL) between survivors and non-survivors. In addition, ROC curves analysis revealed sensitivity and specificity values of 74% and 76%, respectively, at a cut-off of 127 (ng/mL), indicating hepcidin as a good biomarker in predicting the severity and mortality of COVID-19 in ICU patients.
2022
covid-19; hepcidin; icu
01 Pubblicazione su rivista::01a Articolo in rivista
Evaluation of hepcidin level in covid-19 patients admitted to the intensive care unit / Ciotti, Marco; Nuccetelli, Marzia; Pieri, Massimo; Maria Petrangeli, Carlo; Giovannelli, Alfredo; Cosio, Terenzio; Rosa, Luigi; Valenti, Piera; Leonardis, Francesca; Maria Legramante, Jacopo; Bernardini, Sergio; Campione, Elena; Minieri, Marilena. - In: DIAGNOSTICS. - ISSN 2075-4418. - 12:11(2022), pp. 1-9. [10.3390/diagnostics12112665]
File allegati a questo prodotto
File Dimensione Formato  
Ciotti_Evaluation_2022.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 879.33 kB
Formato Adobe PDF
879.33 kB Adobe PDF
Ciotti_preprint_Evaluation_2022.pdf

accesso aperto

Tipologia: Documento in Pre-print (manoscritto inviato all'editore, precedente alla peer review)
Licenza: Creative commons
Dimensione 634.01 kB
Formato Adobe PDF
634.01 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1658972
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact